Systemic Inhibition of Monocyte Chemoattractant Protein-1 (MCP-1; CCL2)

单核细胞趋化蛋白-1(MCP-1;CCL2)的全身抑制

基本信息

  • 批准号:
    7468646
  • 负责人:
  • 金额:
    $ 27.82万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-06-01 至 2013-05-31
  • 项目状态:
    已结题

项目摘要

We have identified monocyte chemoattractact protein - 1 (MCP-1, CCL2) as a novel potent regulator of Drostate cancer proliferation and migration. The ability of CCL2 to influence prostate cancer (PCa) tumorigenesis and metastasis may occur via direct promotional effect on tumor cell growth and function as well as a modulatory effect on the tumor microenvironment by promoting macrophage mobilization and infiltration into the tumor bed. We have demonstrated that PCa cells in vitro and in human cancer tissues exhibit an upregulation of the CCL2 receptor, CCR2. In addition, a major role of CCL2 on tumor growth and metastasis has been linked to its. regulatory role in mediating monocyte / macrophage infiltration into the tumor microenvironment and stimulating a phenotypic change within these immune cells to promote tumor growth (tumor associated macrophages, TAMs). CCL2 has previously been shown to be an important determinant of monocyte / macrophage infiltration in breast, cervix and pancreatic carcinomas and the levels of CCL2 expression have been correlated with the involvement of lymphocyte and macrophage localization n secondary sites of tumor formation. We were the first to establish a direct stimulatory role of CCL2 on PCa cells in vitro. Utilizing anti-human (CNTO888) and anti-mouse (C1142) specific neutralizing antibodies to CCL2, we have demonstrated an inhibition of prostate tumor growth and migration in vivo through direct effects on the PCa cells as well as blocking the infiltration of TAMs into the tumors. The availability of the human antibody CNTO888 to CCL2 will allow us to test our observations and hypothesis in humans: Overall Proposal Hypothesis: Systemic inhibition of monocvte chemoattractant protein -1 (MCP-1; CCL2) will be an effective treatment for prostate cancer. To test this hypothesis we will perform the following specific aims: 1) We will dissect the role of increased CCL2 expression on monocyte mobilization in response to prostate cancer, 2) we will dissect the role of CCL2 on macrophage infiltration and subsequent tumor growth and metastasis of prostate cancer, and 3) we will test the human antibody CNTO888 to CCL2 in patients with prostate cancer. Completion of these experiments will define the role of infiltrating macrophages in prostate cancer biology and characterize the validity of targeting CCL2 for the treatment ol advanced prostate cancer.
我们发现单核细胞趋化蛋白-1(MCP-1,CCL2)是一种新的有效的细胞外信号调节因子。 前列腺癌的增殖和迁移。CCL2对前列腺癌(PCa)的影响 肿瘤的发生和转移可能是通过直接促进肿瘤细胞的生长和功能而发生的 以及通过促进巨噬细胞动员和促进肿瘤微环境的调节作用 渗入肿瘤床。我们已经在体外和人类癌症组织中证明了PCA细胞 表现出CCL2受体CCR2的上调。此外,CCL2在肿瘤生长和生长中的重要作用 转移与其相关。调控单核/巨噬细胞侵袭血管内皮细胞的作用 肿瘤微环境和刺激这些免疫细胞内的表型变化促进肿瘤 生长(肿瘤相关巨噬细胞,TAMs)。CCL2以前已经被证明是一个重要的 乳腺癌、宫颈癌和胰腺癌中单核/巨噬细胞浸润的决定因素及其水平 CCL2的表达与淋巴细胞和巨噬细胞的定位有关 N个肿瘤形成的次要部位。我们首先建立了CCL2对PCa的直接刺激作用 体外培养的细胞。利用抗人(CNTO888)和抗鼠(C1142)特异性中和抗体 CCL2,我们已经证明了通过直接的 对前列腺癌细胞的影响以及阻断TAMs对肿瘤的渗透。可供使用的 抗CCL2的人类抗体CNTO888将使我们能够在人体上测试我们的观察结果和假设: 总体建议假说:全身抑制单核细胞趋化蛋白-1(MCP-1; CCL2)将成为前列腺癌的有效治疗方法。为了检验这一假设,我们将执行 具体目标如下:1)我们将剖析CCL2表达增加在单核细胞动员中的作用 前列腺癌的反应,2)我们将剖析CCL2在巨噬细胞浸润和随后的 前列腺癌的生长和转移;3)检测抗CCL2的人源抗体CNTO888 在前列腺癌患者中。这些实验的完成将确定渗透的作用 巨噬细胞在前列腺癌生物学中的作用及靶向CCL2治疗前列腺癌的有效性 晚期前列腺癌。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ROBERT LOBERG其他文献

ROBERT LOBERG的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ROBERT LOBERG', 18)}}的其他基金

Systemic Inhibition of Monocyte Chemoattractant Protein-1 (MCP-1; CCL2)
单核细胞趋化蛋白-1(MCP-1;CCL2)的全身抑制
  • 批准号:
    8281662
  • 财政年份:
  • 资助金额:
    $ 27.82万
  • 项目类别:
Systemic Inhibition of Monocyte Chemoattractant Protein-1 (MCP-1; CCL2)
单核细胞趋化蛋白-1(MCP-1;CCL2)的全身抑制
  • 批准号:
    8082762
  • 财政年份:
  • 资助金额:
    $ 27.82万
  • 项目类别:
Systemic Inhibition of Monocyte Chemoattractant Protein-1 (MCP-1; CCL2)
单核细胞趋化蛋白-1(MCP-1;CCL2)的全身抑制
  • 批准号:
    8375954
  • 财政年份:
  • 资助金额:
    $ 27.82万
  • 项目类别:
Systemic Inhibition of Monocyte Chemoattractant Protein-1 (MCP-1; CCL2)
单核细胞趋化蛋白-1(MCP-1;CCL2)的全身抑制
  • 批准号:
    7872984
  • 财政年份:
  • 资助金额:
    $ 27.82万
  • 项目类别:

相似海外基金

Predicticting performance of carbon capture in intensified rotating packed beds using CFD
使用 CFD 预测强化旋转填充床中的碳捕获性能
  • 批准号:
    2883569
  • 财政年份:
    2023
  • 资助金额:
    $ 27.82万
  • 项目类别:
    Studentship
Efficient and well-balanced numerical methods for nonhydrostatic three-dimensional shallow flows with moving beds and boundaries
具有移动床和边界的非静水三维浅流的高效且平衡的数值方法
  • 批准号:
    RGPAS-2020-00102
  • 财政年份:
    2022
  • 资助金额:
    $ 27.82万
  • 项目类别:
    Discovery Grants Program - Accelerator Supplements
Quantifying the status and success on restored native oyster Ostrea edulis beds in the Solent.
量化索伦特海峡恢复的本地牡蛎 Ostrea edulis 床的状态和成功。
  • 批准号:
    2759209
  • 财政年份:
    2022
  • 资助金额:
    $ 27.82万
  • 项目类别:
    Studentship
Efficient and well-balanced numerical methods for nonhydrostatic three-dimensional shallow flows with moving beds and boundaries
具有移动床和边界的非静水三维浅流的高效且平衡的数值方法
  • 批准号:
    RGPIN-2020-06278
  • 财政年份:
    2022
  • 资助金额:
    $ 27.82万
  • 项目类别:
    Discovery Grants Program - Individual
Energy to chemicals using direct electrical current flowing through dense beds
利用流过致密床的直接电流将能量转化为化学物质
  • 批准号:
    RGPIN-2019-03912
  • 财政年份:
    2022
  • 资助金额:
    $ 27.82万
  • 项目类别:
    Discovery Grants Program - Individual
Treatment of resected brain tumour beds using nanoparticle enhanced radiotherapy
使用纳米粒子增强放射治疗治疗切除的脑瘤床
  • 批准号:
    10032278
  • 财政年份:
    2022
  • 资助金额:
    $ 27.82万
  • 项目类别:
    Collaborative R&D
SmUPS: Smart Uninterruptable Power Suppy for Home Healthcare Virtual Beds Monitoring and Power Backup
SmUPS:用于家庭医疗保健虚拟床监控和电源备份的智能不间断电源
  • 批准号:
    10045010
  • 财政年份:
    2022
  • 资助金额:
    $ 27.82万
  • 项目类别:
    Grant for R&D
Exosome treatment-induced mechanisms in chronic wound beds - Resubmission - 1
慢性伤口床中外泌体治疗诱导的机制 - 重新提交 - 1
  • 批准号:
    10350276
  • 财政年份:
    2022
  • 资助金额:
    $ 27.82万
  • 项目类别:
Exosome treatment-induced mechanisms in chronic wound beds - Resubmission - 1
慢性伤口床中外泌体治疗诱导的机制 - 重新提交 - 1
  • 批准号:
    10588244
  • 财政年份:
    2022
  • 资助金额:
    $ 27.82万
  • 项目类别:
Research on technology to measure the condition of a wide range of river embankments and river beds in three dimensions in real time and with high accuracy
大范围河堤河床三维实时高精度测量技术研究
  • 批准号:
    22K04653
  • 财政年份:
    2022
  • 资助金额:
    $ 27.82万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了